

LGI1 Antibody (Center) Blocking PeptideSynthetic peptide
Catalog # BP6769c**Specification****LGI1 Antibody (Center) Blocking Peptide - Product Information**Primary Accession [O95970](#)**LGI1 Antibody (Center) Blocking Peptide - Additional Information**

Gene ID 9211

Other NamesLeucine-rich glioma-inactivated protein 1,
Epitempin-1, LGI1, EPT**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6769c](/products/AP6769c) was selected from the Center region of human LGI1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LGI1 Antibody (Center) Blocking Peptide - Protein Information

Name LGI1

Synonyms EPT

LGI1 Antibody (Center) Blocking Peptide - Background

LGI1 contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences.

LGI1 Antibody (Center) Blocking Peptide - References

de Bellescize, J., et al., Epilepsy Res. 85 (1), 118-122 (2009)

Function

Regulates voltage-gated potassium channels assembled from KCNA1, KCNA4 and KCNAB1. It slows down channel inactivation by precluding channel closure mediated by the KCNAB1 subunit. Ligand for ADAM22 that positively regulates synaptic transmission mediated by AMPA-type glutamate receptors (By similarity). Plays a role in suppressing the production of MMP1/3 through the phosphatidylinositol 3-kinase/ERK pathway. May play a role in the control of neuroblastoma cell survival.

Cellular Location

Secreted. Cell junction, synapse.
Note=Isoform 1 but not isoform 2 is secreted. Isoform 1 is enriched in the Golgi apparatus while isoform 2 accumulates in the endoplasmic reticulum

Tissue Location

Predominantly expressed in neural tissues, especially in brain. Expression is reduced in low-grade brain tumors and significantly reduced or absent in malignant gliomas. Isoform 1 is absent in the cerebellum and is detectable in the occipital cortex and hippocampus; higher amounts are observed in the parietal and frontal cortices, putamen, and, particularly, in the temporal neocortex, where it is 3.5 times more abundant than in the hippocampus (at protein level). Isoform 3 shows the highest expression in the occipital cortex and the lowest in the hippocampus (at protein level)

LG11 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)